Samlyn Capital, LLC Exelixis, Inc. Transaction History

Samlyn Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$20.67 - $26.94 $20.9 Million - $27.3 Million	-1,011,903 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$16.46 - $27.42 $732,815 - $1.22 Million	-44,521 Reduced 4.21%	1,011,903 $24 Million
Q1 2020 May 15, 2020	BUY	$14.46 - $21.8 $15.3 Million - $23 Million	1,056,424 New	1,056,424 $18.2 Million
Q2 2019 Aug 14, 2019	SELL	$18.93 - $24.75 $9.06 Million - $11.8 Million	-478,532 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$19.6 - $24.76 $6.35 Million - $8.03 Million	-324,129 Reduced 40.38%	478,532 $11.4 Million
Q4 2018 Feb 14, 2019	BUY	$13.65 - $21.8 $11 Million - $17.5 Million	802,661 New	802,661 $15.8 Million

503

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Samlyn Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Samlyn Capital, LLC with notifications on news.